Document is current
Any future updates will be listed below
-
Authors
Staniszewska, Magdalena
Hübner, Ralph
Locatelli, Camilla
Howard, Douglas
Forni, Matilde
Man, Francis
Schoultz, Bent Wilhelm
Nuruddin, Syed
Norberg-Schulz Hagen, Ingrid Sofie
Mosessian, Sherly
Herrmann, Ken
von Kiedrowski, Valeska
Lückerath, Katharina https://orcid.org/0000-0001-6109-2066
-
Funding
Funding for this research was provided by:
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 16 February 2026
First Online: 28 February 2026
Change Date: 10 May 2026
Change Type: Update
Change Details: This article has been updated to correct the missing corresponding author indication.
Declarations
:
: Animal studies were approved by the local ethics committee (FOTS ID 30696, Norway).
: Not applicable.
: KL: personal fees from Sofie Biosciences, research support from Novartis, AMGEN, Mariana Oncology. KH: consultant fees from Advanced Accelerator Applications, a Novartis company, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, Molecular Partners, NVision, POINT Biopharma, Pfizer, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, and Theragnostics, ymabs, research grants from Advanced Accelerator Applications, a Novartis company, Boston Scientific, Janssen, stock or other ownership interests with: AdvanCell, Aktis Oncology, Convergent, NVision, Pharma 15, Sofie Biosciences. FM and MF are employees and shareholders of GE Healthcare, which holds the rights to develop and commercialize the test items used in the study. SM is an employee of Sofie Biosciences Inc. All other authors have nothing to disclose.
